Biotechnology

Filter

Current filters:

None

Popular Filters

1930 to 1954 of 2434 results

FDA delays approval of Navidea's Lymphoseek

11-09-2012

US biotech company Navidea Biopharmaceuticals (NYSE: NAVB) says it has received a Complete Response Letter…

BiotechnologyLymphoseekNavidea BiopharmaceuticalsNorth AmericaRegulation

European vaccines market forecast to grow to $12.05 billion in 2018

11-09-2012

As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalProductionVaccines

NovaBay entering transformational period, say Edison analysts

10-09-2012

US biotech firm NovaBay Pharmaceutical (Nasdaq: NBY) is entering a potentially transformational 12-month…

Antibiotics and Infectious diseasesBiotechnologyFinancialLicensingNeutroPhaseNovaBay PharmaceuticalNVC422Research

Recent therapeutics IPOs outperform, but life sciences offerings a mixed bag, says Burrill

10-09-2012

Therapeutics companies that have gone public since 2011 are up 27.1 percent as of the end of August 2012,…

BiotechnologyFinancial

Peregrine leaps 56% as bavituximab shown to double NSCLC patient survival

10-09-2012

Shares of US biotech firm Peregrine Pharmaceuticals (Nasdaq: PPHM) rocketed 56.4% to $4.80 last Friday,…

bavituximabBiotechnologyOncologyPeregrine PharmaceuticalsPharmaceuticalResearch

Edison analysts' take on Basilea outlook

10-09-2012

The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica…

Antibiotics and Infectious diseasesBasilea PharmaceuticaBiotechnologyceftobiproleFinancialisavuconazoleOncologyResearchToctino

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Roche showcases R&D pipeline, with 72 NMEs and focus on personalized medicines

06-09-2012

At a London investor event this week, Swiss drug major Roche (ROG: SIX) presented an update on its strategy,…

BiotechnologyOncologyPharmaceuticalResearchRoche

Gene suppression significantly prolongs life in ALS: Potential for future blockbuster treatment?

06-09-2012

Advances in the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease,…

BiotechnologyNeurologicalResearch

Merck Serono gains rights to Ph II cancer drug from Symphogen for up to 475 million euros

06-09-2012

Privately-held Danish drug developer Symphogen A/S announced this morning that it has signed an exclusive…

BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceuticalSym004Symphogen

Myrexis returns rights to Azixa to EpiCept

06-09-2012

US drug developer EpiCept (Nasdaq: EPCT) says it has received notice of termination, effective as of…

AzixaBiotechnologyEpiCeptLicensingMyrexisOncologyPharmaceutical

Most US and European physicians believe automatic substitution of biosimilars is a bad idea

05-09-2012

Specialist physicians surveyed in the USA and Europe are generally opposed to pharmacy-level automatic…

BiotechnologyDiabetesEuropeGenericsMarkets & MarketingNorth America

FDA approves initiation of a Phase IIb study of Genfit's GFT505

05-09-2012

French biotech firm Genfit (Alternext: ALGFT) says that the US Food and Drug Administration has approved…

Anti-viralsBiotechnologyGenfitGFT505RegulationResearch

Oncology drugs get faster approvals than non-cancer drugs in USA, but opposite case in Europe, Tufts research finds

05-09-2012

Approval times for new oncology drugs in the USA during the last decade were shorter than those for non-oncology…

BiotechnologyEuropeNorth AmericaOncologyPharmaceuticalRegulationResearch

Headache for Pharma as R&D spending climbs while NME approvals fall

04-09-2012

Low research and development (R&D) productivity, combined with the patent cliff and a stringent US Food…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearch

Galapagos unit in CNS discovery deal with Ono Pharma

03-09-2012

Belgian biotech firm Galapagos NV (Euronext: GLPG) says that its service division BioFocus and Japanese…

BioFocusBiotechnologyGalapagosNeurologicalOno PharmaceuticalPharmaceuticalResearch

Merck Serono creates second company under EPP

03-09-2012

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), has established Quartz Bio, the second spin-off…

BiotechnologyManagementMerck KGaAMerck SeronoPharmaceuticalQuartz Bio

FDA backs Medivation and Astellas' prostate cancer drug Xtandi

03-09-2012

USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US…

Astellas PharmaBiotechnologyenzalutamideMedivationNorth AmericaOncologyPharmaceuticalRegulationXtandi

UK biotech calls for "mass market" citizens' innovation funds

03-09-2012

The outlook for the UK economy remains flat and innovative small- and medium-sized enterprises (SMEs)…

BiotechnologyEuropeFinancialResearch

1930 to 1954 of 2434 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top